February 15, 2022

Qorvo® Biotechnologies Awarded $4.1M NIH Contract for SARS-CoV-2/Flu Combo and Antigen Pooling

By admin In News, Technology No comments

Qorvo® Biotechnologies Awarded $4.1M NIH Contract for SARS-CoV-2/Flu Combo and Antigen Pooling

The contract will help advance the clinical trials and market launch of both a SARS-CoV-2/Flu Combo Assay and SARS-CoV-2 Antigen Pooling on the Qorvo Omnia™ diagnostic test platform.

The contract will help advance the clinical trials and market launch of both a SARS-CoV-2/Flu Combo Assay and SARS-CoV-2 Antigen Pooling on the Qorvo Omnia™ diagnostic test platform.

http://www.microwavejournal.com/rss/topic/3369-industry-newsIndustry Newshttps://www.microwavejournal.com/articles/37618-qorvo-biotechnologies-awarded-41m-nih-contract-for-sars-cov-2-flu-combo-and-antigen-pooling

Powered by WPeMatico